Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Transplantation Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Transplantation Patients.
Wall SA, Olin R, Bhatt V, Chhabra S, Munshi P, Hacker E, Hashmi S, Hassel H, Howard D, Jayani R, Lin R, McCurdy S, Mishra A, Murthy H, Popat U, Wood W, Rosko AE, Artz A. Wall SA, et al. Among authors: bhatt v. Transplant Cell Ther. 2023 Oct;29(10):632.e1-632.e10. doi: 10.1016/j.jtct.2023.04.020. Epub 2023 May 1. Transplant Cell Ther. 2023. PMID: 37137442 Free article. Review.
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR. Sung AD, et al. Among authors: bhatt vr. Transplant Cell Ther. 2024 Apr;30(4):415.e1-415.e16. doi: 10.1016/j.jtct.2024.01.062. Epub 2024 Jan 17. Transplant Cell Ther. 2024. PMID: 38242440
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM. Shallis RM, et al. Lancet Haematol. 2023 Sep;10(9):e767-e776. doi: 10.1016/S2352-3026(23)00159-X. Epub 2023 Aug 9. Lancet Haematol. 2023. PMID: 37572683 Review.
Response to the letter to the editor.
Bhatt VR. Bhatt VR. J Geriatr Oncol. 2024 Apr;15(3):101712. doi: 10.1016/j.jgo.2024.101712. J Geriatr Oncol. 2024. PMID: 38575252 No abstract available.
Synthesis, characterization, and biological activities of novel organometallic compounds of rhenium(I) with 2-(2-benzylidenehydrazinyl) benzothiazole Schiff-base derivatives: Molecular docking, ADME, and DFT studies.
Padariya AD, Savaliya NK, Parekh HM, Bhatt BS, Bhatt VD, Patel MN. Padariya AD, et al. Among authors: bhatt vd. Comput Biol Chem. 2024 Dec 16;115:108313. doi: 10.1016/j.compbiolchem.2024.108313. Online ahead of print. Comput Biol Chem. 2024. PMID: 39705780
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
Davids MS, Brander DM, Alvarado Valero Y, Diefenbach CS, Egan DN, Dinner SN, Javidi-Sharifi N, Al Malki MM, Begna K, Bhatt VR, Abedin S, Cook R, Collins MC, Roleder C, Dominguez EC, Rajagopalan P, Wiley SE, Ghalie RG, Danilov AV. Davids MS, et al. Among authors: bhatt vr. Blood Adv. 2024 Dec 20:bloodadvances.2024014633. doi: 10.1182/bloodadvances.2024014633. Online ahead of print. Blood Adv. 2024. PMID: 39705540
547 results